ACTRN12609000044224TerminatedPhase 2
A Phase II, Study to Evaluate The Efficacy and Safety of Dantonic 'Registered trade mark' in Patients with Chronic Stable Angina Pectoris
CNS Pty Ltd0 sites70 target enrollmentStarted: January 20, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Enrollment
- 70
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to 80 Years (—)
- Sex
- All
Inclusion Criteria
- •1.Male or female aged 18 to 80 years.
- •2.Females of childbearing potential must have a negative pregnancy test, not be breast feeding and established on a method of contraception that in the investigator’s opinion is acceptable. Females must agree to remain on their established method of contraception through their participation in the study.
- •3.Evidence of coronary artery disease that consists of a well-documented medical history of myocardial infarction or significant coronary artery disease with non-invasive or angiographic confirmation.
- •4.Symptoms that support the diagnosis of chronic stable angina and/or a history of an abnormal exercise response limited by angina and/or electrocardiograph changes.
- •5.Moderate (Class II or Class III according to Canadian Cardiovascular Society Angina Classification) angina pectoris
- •6.Naive patient or patient who’s Total Exercise Duration (TED) is between 3 to 7 minutes in ETT on Standard Bruce Protocol, and the difference in TED must be no more than 15% between the two screen examinations on day -7 and day 0.
- •7.Patient must be able to withdraw all anti-angina regimen (except short-acting nitroglycerin, beta-blockers or calcium channel blockers), that were used prior to this initial visit.
- •8.Patient must understand and be willing to comply with protocol visit schedule.
- •9.Patient must be able and willing to give informed consent.
Exclusion Criteria
- •1.Contraindication to perform treadmill Exercise Tolerance Test (ETT).
- •2.Presence of pre-exercise ST-segment depression of at least 1 mm in any lead, left bundle branch block, digoxin therapy, Left Ventricular Hypertrophy (LVH) and Wolff-Parkinson-White (WPW) syndrome or other factors that could, to the investigator’s opinion, interfere with exercise electrocardiograph interpretation.
- •3.Clinically severe arrhythmias or atrioventricular conduction block greater than first degree.
- •4.Clinically severe co-morbidities, including hepatic or renal dysfunction, pulmonary hypertension, chronic obstructive pulmonary disease, current of cerebral hemorrhage, or seizure disorders that required anticonvulsant medication.
- •5.Recent history of congestive heart failure (occurrence within two weeks), unstable angina, severe valvular disease, severe hypertension, severe anemia, suspected or known dissecting aneurysm, acute myocarditis or pericarditis, thrombophlebitis or pulmonary embolism or recent myocardial infarction within three months of study entry.
- •6.Current bleeding diathesis, or current treatment with warfarin and/or on other oral anticoagulants, and inability to discontinue these medications.
- •7.Implanted pacemaker.
- •8.Aspirin and/or other platelet inhibitors including Clopidogrel, started less than 30 days prior to the signing of informed consent.
- •9.Pregnancy or lactation.
- •10.Inability to discontinue existing chronic nitrate regimen (e.g. long acting nitroglycerin) and other anti-angina medications except for beta-blockers or calcium channel blockers.
- •11.Participation in any other clinical trial or receipt of an investigational drug within 90 days prior to initial visit.
- •12.Previous participation in this study.
- •13.Substance abuse. Patients with a recent history (within the last 2 years) of alcoholism or known drug dependence.
- •14. Patient is a family member or relative of the study site staff.
- •15. Investigator’s opinion that the individual is not appropriate for the trial
Investigators
Similar Trials
Completed
Phase 2
Phase 2 study to evaluate the efficacy and the safety of clarithromycin, lenalidomide and dexamethasone (Personalized BiRd) for patients with relapsed or refractory multiple myelomamultiple myelomaJPRN-UMIN000013467Yokohama Municipal Citizen's Hospital12
Active, not recruiting
Phase 2
Efficacy and safety of polyglycolic acid sheet for the prevention of infectious complication after laparoscopic surgery for gastric cancerIntraperitoneal infectious complicationsPostoperative ComplicationsJPRN-jRCTs052210188Obama Kazutaka210
Active, not recruiting
Phase 1
A Phase II Study to determine the efficacy and safety of conventional dose oral Treosulfan in patients with advanced pre-treated Ewing’s Sarcoma - OTISEUCTR2005-003254-10-GBniversity College London25
Active, not recruiting
Phase 1
A phase II study investigating the efficacy and safety of Vvax001, a therapeutic cancer vaccine, in patients with premalignant cervical lesions.EUCTR2019-004050-29-NLniversity Medical Center Groningen18
Recruiting
Phase 2
A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia.NL-OMON55191niversitair Medisch Centrum Groningen18